Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - Study design and patient demographics

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 1, 2004, Pages 51-63

  Hawkey, C J ^a   Farkouh, M ^b   Gitton, X ^c   Ehrsam, E ^c   Huels, J ^c   Richardson, P ^d  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIEULAFOY DISEASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUODENUM ULCER; ESOPHAGUS ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METHODOLOGY; NEPHROTOXICITY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEALTH STATUS; HUMANS; IBUPROFEN; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; ORGANIC CHEMICALS; OSTEOARTHRITIS; PEPTIC ULCER; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 3142718793     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02026.x     Document Type: Article

References (28)

1. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
3. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
4. Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52: 600-8.
5. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
6. Silverstein FE, Faich G, Golstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
8. Lu HL. Statistical reviewer briefing document for the Advisory Committee. 14 June 2000. Available at http://www.fda.gov/oh-rms/dockets/ac/01/briefing/ 3677b1_04_stats.doc. Accessed 14 April 2004.
9. Li Q. Statistical reviewer briefing document for the Advisory Committee. 29 June 2000. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_04_stats.pdf. Accessed 14 April 2004.
10. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001; 286: 2398.
11. VIOXX US Prescribing Information. Available at http://www.vioxx.com/ vioxx/shared/documents/english/pi.pdf. Accessed 2 December 2003.
12. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50: 661-7.
13. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47: 349-55.
14. Konstam MA, Weir MR. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 2002; 69(Suppl. 1): S147-52.
15. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
16. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol 2001; 19(6 Suppl. 25): S15-22.
17. Marshall PJ, Berry C, Wasvary J, et al. The in-vitro and in-vivo selectivity of lumiracoxib, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002; 61 (Suppl. 1): 259 (Abstract SAT0013).
18. Mangold JB, Gu H, Rodriguez LC, Bonner J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004; 32: 566-71.
19. Hawkey CJ, PUCCINI (Prevention of ulcers with COX189 compared with ibuprofen in NSAID investigation) Group. Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Gastroenterology 2002; 122(4 Suppl.1): A-345 (Abstract M1732).
20. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey CJ. Gastroduodenal safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 1): 171 (Abstract THU0203).
21. Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004; 2: 113-20.
22. Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003; 18: 533-41.
23. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039-49.
24. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33: 1601-10.
25. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505-14.
26. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. J Am Coll Cardiol 1999; 34: 1348-59.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
28. DeMets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med 1994; 13: 1341-1352.